20 articles
Baylor researchers investigated whether glutathione precursors glycine and NAC could reverse oxidative stress and mitochondrial dysfunction in COVID-19.
Cornell study tests whether N-acetylcysteine can restore protective antioxidants in Parkinson's patients' brains using advanced brain imaging.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
A completed Nestlé-sponsored trial directly compared three popular NAD precursors head-to-head in healthy adults.
Maastricht University investigated whether NA, NAM, and tryptophan together could restore mitochondrial function in physically compromised older adults.
A Phase 1/2 trial tests whether nicotinamide riboside can restore NAD+ balance and improve heart function in systolic HF patients.
New study evaluates reduced nicotinamide mononucleotide for anti-aging benefits, measuring biological age and physical performance.
A completed Maastricht University trial tests whether pairing NR supplementation with exercise can boost NAD+ levels and reverse metabolic dysfunction in overweight adults.
A completed pharmacokinetic study tracks NAD precursors NR and NMN from bloodstream to brain, filling a critical gap in human data.
First major clinical trial tests NMN supplement doses up to 900mg in middle-aged adults for anti-aging effects.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
A completed Mayo Clinic trial examined whether nicotinamide riboside can preserve bone density, muscle mass, and metabolic function in healthy older adults.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Small trial explores how popular greens supplement affects microbiome and blood nutrient markers in healthy adults over 7 weeks.
12-week trial tests supplement combination for improving lipid metabolism and appetite control in overweight middle-aged adults.
Chinese researchers tested nucleotide supplements against aging markers in 122 participants over 4 months with promising early results.
Vanderbilt study tests whether reducing calcium-to-magnesium ratios through targeted supplementation can improve brain function in seniors.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
A completed RCT from the University of Copenhagen tests whether aerobic exercise, time-restricted feeding, or NR supplementation best improves biological aging markers in healthy older adults.
